http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2444575-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0802 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4741 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 |
| filingDate | 2007-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03a05a0216066631e1286d0e2b9164af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f06502e608020bba749648dff876e0ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecdb705f14c2cf7868f33049786fefeb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9fccc479e6a736f267778cec09d9a46 |
| publicationDate | 2014-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2444575-T3 |
| titleOfInvention | HCV NS3 protease inhibitors |
| abstract | A compound of formula (I): ** Formula ** or a pharmaceutically acceptable salt or hydrate thereof, in which: it is selected from the group of rings consisting of: 1) aryl, 2) C3-C8 cycloalkyl; and 3) a heterocyclic ring system, in which the junction points with the variables Y and X are independently selected from a first pair of atoms comprising a first ring carbon atom and a second carbon atom of the ring, and a second pair of atoms comprising a ring carbon atom and a ring nitrogen atom, and the heterocyclic ring system is selected from the group consisting of: a) a saturated or unsaturated monocyclic ring of 5 or 6 members with 1, 2 or 3 atoms of the heteroatomic ring selected from the group consisting of N, O or S; b) a saturated, unsaturated bicyclic ring of 8, 9 or 10 members with 1, 2 or 3 heteroatomic ring atoms selected from the group consisting of N, O or S; and c) a saturated or unsaturated tricyclic ring of 11 to 15 members with 1, 2, 3 or 4 atoms of the heteroatomic ring selected from the group consisting of N, O or S, wherein said aryl, cycloalkyl ring or heterocyclic ring is unsubstituted , mono-substituted with R5, disubstituted with groups selected, independently, from R5, trisubstituted with groups selected, independently, from R5, or tetrasubstituted with selected groups, in an independent way, between R5, and where any atom of the Stable S or N heterocyclic ring is unsubstituted or substituted with oxo, said R5 substitutions of the heterocyclic ring being one or more carbon or nitrogen atoms of the heterocyclic ring. |
| priorityDate | 2006-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 517.